FDA Approves Pediatric Dose of Pancreatic Enzyme Supplement CREON®
June 16, 2011
Abbott Laboratories announced that the U.S. Food and Drug Administration has approved a dosing of its pancreatic enzyme replacement therapy CREON® (pancrelipase) sized specifically for infants.
The new lower-strength capsule will allow for a more precise and consistent dose to be given to infants who receive CREON® to treat pancreatic enzyme insufficiency caused by cystic fibrosis. Pancreatic enzymes help the body absorb essential nutrients.
Almost 90 percent of people with CF take pancreatic enzyme supplements, without which they would not survive.
Read more in the full release from Abbott.